Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics

This study has been withdrawn prior to enrollment.
Information provided by:
Novartis Identifier:
First received: October 16, 2009
Last updated: October 4, 2010
Last verified: October 2010
This study will evaluate the correct use of sequential formoterol and budesonide inhaler capsule treatment via Aerolizer and patient satisfaction in adult asthmatics.

Condition Intervention Phase
Drug: Foradil Combi (Formoterol-budesonide)
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm, 12 Week, Multicentre, Open Label, Phase IV Study to Evaluate Correct Use of and Patient Satisfaction From Sequential Use of Formoterol and Budesonide Inhaler Capsules Via Aerolizer™ Device in Patients With Asthma.

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Proper use of Foradil Combi [ Time Frame: Day 0, Day 30, Day 90 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Asthma control test [ Time Frame: Day 0, Day 30, Day 90 ] [ Designated as safety issue: No ]
  • Ease of use: FSI-10 Questionnaire [ Time Frame: Day 30, Day 90 ] [ Designated as safety issue: No ]
  • Patient Satisfaction: PSAM and FSI-10 [ Time Frame: Evaluations will be made at visit 2 (Day 30± 1) and 3 (Day 90± 3) ] [ Designated as safety issue: No ]
  • Safety: Adverse events and severe adverse events [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 110
Study Start Date: June 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Formoterol and Budesonide Drug: Foradil Combi (Formoterol-budesonide)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate persistent asthmatic patients.
  • No previous Aerolizer experience.

Exclusion Criteria:

  • Life-threatening asthma: A subject must not have life-threatening asthma as a history of significant asthma episode(s)requiring intubation associated with hypercapnia, respiratory arrest or hypoxic seizures, or asthma-related syncopal episode(s).
  • Worsening of asthma: A subject must not have experienced a worsening of asthma which involved a hospitalization within 6 months of screening, or an emergency room visit three or more times in the past 6 months, or use of oral corticosteroids for worsening asthma within 3 months of screening.
  • Unstable asthma: During screening period, a patient requires the use of >8 puffs/day of salbutamol 100 mcg per actuation pMDI on two consecutive days.
  • A subject must not have had an upper respiratory tract infection within 4 weeks of screening.
  • FEV1< 60% at screening.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00997477

Novartis Investigator Site
Ankara, Turkey
Novarits Investigator Site
Istanbul, Turkey
Novartis Investigator Site
Istanbul, Turkey
Novartis Investigator Site
Izmir, Turkey
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Medical Department, Novartis Pharmaceuticals Identifier: NCT00997477     History of Changes
Other Study ID Numbers: CFOR258FTR03
Study First Received: October 16, 2009
Last Updated: October 4, 2010
Health Authority: Turkey: Ministry of Health

Keywords provided by Novartis:

Additional relevant MeSH terms:
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on November 27, 2015